Sunday, June 1, 2003
Cancer Patient Advocates gather after today's Live Webcast
A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced non-nasopharygeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first-l Bladder preservation with induction chemotherapy (carboplatin/paclitaxel) followed by radiotherapy with concurrent paclitaxel. A study of the Hellenic Cooperative Oncology Group Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer. Interim analysis of a multicenter phase III trial Early Study Results Promising: Oral Medication Active Against Skin Cancer Early Study Results Promising: Oral Medication Active Against Skin Cancer Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperati Induction chemotherapy following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB) Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leukovorin (LV) + levamisole ( Isolated CNS relapse of acute lymphoblastic leukemia (ALL) treated with intensive systemic chemotherapy and delayed CNS radiation: A Pediatric Oncology Group Study Late cardiotoxicity of mediastinal irradiation Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nscls: RTOG 94-10 Neoadjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: A matched case control study OncoLink TV: Special Live Webcast from ASCO 2003 Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) Phase III dose-randomization study of imatinib mesylate (STI571, Gleevac) for GIST: Intergroup S0003 early results Radiation Therapy Oncology Group (RTOG) 9514: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade (HG) soft tissue sarcomas (STS) of the extremities and body wall Subsequent neoplasms (SNs) of the central nervous system (CNS) in survivors of childhood cancer: a case/control study from the Children's Cancer Survivor Study (CCSS) Ten-Year outcomes for elderly women treated with breast-conserving surgery and definitive breast irradiation for early stage breast cancer. The impact of concurrent versus sequential tamoxifen and radiation therapy in breast cancer patients undergoing breast conservation therapy. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort.